Cover Image
市場調查報告書

M&A:全球成藥產業的企業合併、收購 (M&A) 趨勢分析

M&A: A Nicholas Hall Report on Global OTC Mergers & Acquisitions

出版商 Nicholas Hall & Company 商品編碼 348312
出版日期 內容資訊 英文 241 Pages
訂單完成後即時交付
價格
Back to Top
M&A:全球成藥產業的企業合併、收購 (M&A) 趨勢分析 M&A: A Nicholas Hall Report on Global OTC Mergers & Acquisitions
出版日期: 2016年04月08日 內容資訊: 英文 241 Pages
簡介

由於現在有機手段的企業成長困難,企業合併、收購 (M&A) 在成藥產業中,不論企業的大小成為重要的成長手段。大企業的情況是,投資幾十億美元收買其他公司資產的景象成為日常性之事。可是,OTC市場非常細分化,最大3家公司總合也只有佔有率15%以下,對中小企業來說自己M&A以求規模擴大還有充分的空間。

本報告提供全球成藥產業的企業合併、收購 (M&A) 的趨勢相關分析,全球、各地區、各國近幾年的M&A數量,及大OTC企業的M&A的數量、案例、未來預測,代表性M&A議案的內容、目標、成果,過去10年的M&A趨勢等相關調查。

概要

近幾年的M&A分析 (過去4年份)

M&A的趨勢

大OTC企業的M&A

  • Bayer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi
  • RB
  • Procter & Gamble
  • Boehringer Ingelheim
  • 武田藥品工業
  • 大正製藥
  • Novartis
  • NBTY
  • Mondelez
  • 大塚製藥
  • China Resources 999
  • Valeant
  • Prestige Brands
  • Perrigo
  • Merck
  • 樂敦
  • Kalbe
  • Konimex
  • Lil' Drug Store
  • Matrixx
  • Mega Lifesciences
  • Merz
  • Midway Importing
  • Molnlycke
  • Mommy's Bliss
  • Mundipharma
  • Mylan
  • Natulab
  • NeilMed
  • Nelsons
  • NeoCell
  • Nordic Naturals
  • Norgine
  • Orkla Health (舊Axellus)
  • Orthomol
  • PharmaCare
  • Pharmstandard (含OTCPharm)
  • Picasso Candamo
  • Pohl Boskamp
  • ProPhase Labs
  • Queisser
  • Quincy Bioscience
  • ReNew Life
  • Ricola
  • Servier
  • Shenyang Hongyao
  • Sido Muncul
  • Similasan
  • Stada
  • Standard Homeopathic
  • Sun Pharma
  • Tecnoquimicas
  • Tempo
  • Trimb Healthcare
  • Unipharm
  • Urgo (舊Vivasante)
  • Ursapharm
  • Vitabiotics
  • Walmark
  • Woerwag
  • Zambon
  • Zarbee's

OTC企業的未來的願景和,今後的M&A

附錄:M&A的登記數量 (過去10年份)

目錄

With organic growth seemingly ever harder to come by, M&A has become vital to OTC players large and small. For those aiming for the very top, creativity in the multi-billion dollar deals has become the trend, with the exchange of assets becoming increasingly commonplace. But in a highly fragmented market, where the Top 3 OTC giants account for less than 15% of the playing field, there is still plenty for small and medium-sized players to tuck into - numerous smaller deals have also helped to reshape the OTC landscape in recent years. All of this, and more, can be found in this invaluable report.

Included in this publication:

  • M&A Review 2013-16, with detailed analysis of the period's key deals on a global, regional and local level
  • M&A at the OTC Top Table, including profiles of the leading 20 OTC marketers, including Bayer, GSK, J&J and Sanofi, looking at past highlights and future direction
  • Leading M&A targets, featuring 100 ripe acquisition / j-v targets for your company, including assets and sales
  • Appendix: M&A Register 2005-16, listing all the deals with an OTC impact back to 2005
  • And more!

Table of Contents

Overview

M&A Review 2013-16

M&A Trends

M&A at the OTC Top Table

  • Bayer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi
  • RB
  • Procter & Gamble
  • Boehringer Ingelheim
  • Takeda
  • Taisho
  • Novartis
  • NBTY
  • Mondelez
  • Otsuka
  • China Resources 999
  • Valeant
  • Prestige Brands
  • Perrigo
  • Merck
  • Rohto
  • Kalbe
  • Konimex
  • Lil' Drug Store
  • Matrixx
  • Mega Lifesciences
  • Merz
  • Midway Importing
  • Mölnlycke
  • Mommy's Bliss
  • Mundipharma
  • Mylan
  • Natulab
  • NeilMed
  • Nelsons
  • NeoCell
  • Nordic Naturals
  • Norgine
  • Orkla Health (previously Axellus)
  • Orthomol
  • PharmaCare
  • Pharmstandard (including OTCPharm)
  • Picasso Candamo
  • Pohl Boskamp
  • ProPhase Labs
  • Queisser
  • Quincy Bioscience
  • ReNew Life
  • Ricola
  • Servier
  • Shenyang Hongyao
  • Sido Muncul
  • Similasan
  • Stada
  • Standard Homeopathic
  • Sun Pharma
  • Tecnoquímicas
  • Tempo
  • Trimb Healthcare
  • Unipharm
  • Urgo (previously Vivasanté)
  • Ursapharm
  • Vitabiotics
  • Walmark
  • Woerwag
  • Zambon
  • Zarbee's

Eye on the OTC Horizon & Future of M&A

Appendix: M&A Register 2005-16

Back to Top